메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.

AUCKLAND, New Zealand, Jan. 23, 2026 -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in the Journal of Trauma and Injury. MASTRR is the largest ongoing prospective, multicenter observational study to collect patient data from the use of a bioscaffold in complex reconstruction. To date, over 450 patients have been enrolled. The study, titled "Vascularized Tissue Coverage of Trauma and Acute Care Surgery Defects with Ovine For
- 김갑성 기자
- 2026-01-23 03:13
Tradeify Announces Partnership with UFC Legend, Israel Adesanya

Adesanya joins Tradeify as Global Brand Ambassador Announcement comes ahead of the UFC icon's return to the octagon against Joe Pyfer at UFC Seattle on March 28 Partnership marks the second chapter of Tradeify's Champion Mindset campaign MIAMI, Jan. 23, 2026 -- Tradeify, the global trader evaluation platform, today announces a long-term partnership with UFC legend and two-time middleweight champion Israel Adesanya, who joins the brand as its new Global Brand Ambassador. The Champion Mindset, Chapter II: Adaptability with Israel Adesanya The partners
- 황정호 기자
- 2026-01-23 03:00
Elvira Dyangani Ose Appointed Artistic Director of the Second Edition of Public Art Abu Dhabi Biennial

ABU DHABI, UAE, Jan. 22, 2026 -- The Department of Culture and Tourism – Abu Dhabi has appointed Elvira Dyangani Ose as Artistic Director of the Public Art Abu Dhabi Biennial to curate its second edition which opens in the autumn of 2026 and runs into 2027. Building on the success of the inaugural edition that opened in 2024, the next edition of the Public Art Abu Dhabi Biennial, under Dyangani Ose's direction, will transform Abu Dhabi once again into an emirate-wide celebration of public art, culture and community. The much-lauded inaugural edition of
- 김장윤(JASON KIM) 기자
- 2026-01-22 23:10
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines

[ 메디채널 김갑성 기자 ] New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks Advances Insilico's vision of Pharmaceutical Superintelligence (PSI) CAMBRIDGE, Mass., Jan. 22, 2026 -- Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of Science MMAI Gym, a domain-specific training environment desig
- 김갑성 기자
- 2026-01-22 22:37
Mindray Unveils Three-Pillar Growth Strategy at 2026 J.P. Morgan Healthcare Conference, Paving the Way for Next Decade of Global Healthcare Innovation

SHENZHEN, China, Jan. 22, 2026 -- May Li, Board Secretary of Mindray Medical (300760.SZ), delivered a keynote speech at the 44th J.P. Morgan Healthcare Conference (JPM Conference) on January 15, 2026, outlining the company's strategic vision for the next decade centered on three core pillars: Globalization, Recurring Business Expansion, and Intelli-Digitalization. The speech also showcased significant progress in Mindray's Large Language Model (LLM) product family and innovative solutions that are redefining clinical excellence worldwide. Globalization: Deepening Localization t
- 김갑성 기자
- 2026-01-22 22:11
Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.

SHANGHAI, Jan. 22, 2026 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors. The Phase I/II study (NCT07216560) represents the first-in-human (FIH) study of 7MW4911 in the United States. The study aims to evaluate the safety, pharmacokinetics and efficacy
- 김갑성 기자
- 2026-01-22 22:00
Jin Medical Announces the Official Commencement Date of Chuzhou Facility

CHANGZHOU, China, Jan. 22, 2026 -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that its wholly-owned subsidiary, Zhongjin Medical Equipment (Anhui) Co., Ltd., has made significant progress in the final construction of its manufacturing facility in Chuzhou, Anhui Province, China. The Company is projected to launch full capacity production by the end of April 2026. The Company completed regulatory filings wit
- 김갑성 기자
- 2026-01-22 21:57
Global Times: China's GDP expands 5% to hit 140-trillion-yuan mark in 2025, meeting growth target despite serious headwinds

BEIJING, Jan. 22, 2026 -- China's GDP grew at 5 percent year-on-year to 140.19 trillion yuan ($20.13 trillion) in 2025, data from the National Bureau of Statistics (NBS) showed on Monday, meeting the annual growth target of around 5 percent and surpassing the 140-trillion-yuan threshold for the first time. Observers said the upbeat data underscored the resilience and vitality of the world's second-largest economy despite multiple downward pressures. They added that such growth momentum will continue to position China as a beacon of stability and the locomotive of the world economy. &n
- 황정호 기자
- 2026-01-22 21:44
Teleport raises USD 50 million pre-IPO capital at USD 500 million valuation to scale model globally

[ 메디채널 황정호 기자 ] Teleport set to accelerate the growth of its unique asset-light model with growth capital injection from HPS Investment Partners to better serve cross border eCommerce in key global markets KUALA LUMPUR, Malaysia, Jan. 22, 2026 -- Teleport signed a Subscription Agreement with funds managed by HPS Investment Partners today for the issuance of Redeemable Convertible Perpetual Securities (RCPS) to raise a total consideration of USD50 million as pre-IPO growth capital. HPS Investment Partners is a leading global alternative investment firm. This raise value
- 황정호 기자
- 2026-01-22 21:31
accesso® Expands Venue-Controlled Resale Capability

[ 메디채널 김장윤(JASON KIM) 기자 ] Partnership with menta tech gives venues verified, white-label resale while keeping control of pricing, data and guest relationships. ORLANDO, Fla., Jan. 22, 2026 -- accesso Technology Group (AIM: ACSO), a leading provider of ticketing, commerce, distribution and guest experience technology for live entertainment and attractions, today announced an expanded partnership with menta tech to introduce a venue-controlled, verified secondary ticketing marketplace across its platform. The partnership enables venues using accesso ShoWareSM technology
- 김장윤(JASON KIM) 기자
- 2026-01-22 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-24_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 24일 23시 20분